1. International Breast Cancer Study Group: Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial. J Natl Cancer Inst 2003; 95: 1833–46.
2. de Haes H, Olschewski M, Kaufmann M et al. Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: The Zoladex Early Breast Cancer Res Association Trialists Group. J Clin Oncol 2003; 21: 4510–6.
3. Nystedt M, Berglund G, Bolund C et al. Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: A prospective randomized study. J Clin Oncol 2003; 21: 1836–44.
4. Goodwin PJ. Reversible ovarian ablation or chemotherapy: Are we ready for quality of life to guide adjuvant treatment decisions in breast cancer? J Clin Oncol 2003; 21: 4474–5.
5. Wenzel LB, Fairclough DL, Brady MJ et al. Age-related differences in the quality of life of breast carcinoma patients after treatment. Cancer 1999; 86: 1768–74.
6. Ganz PA, Rowland JH, Desmond K et al. Life after breast cancer: Understanding women's health-related quality of life and sexual functioning. J Clin Oncol 1998; 16: 501–14.
7. Broeckel JA, Jacobsen PB, Balducci L et al. Quality of life after adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 2000; 62: 141–50.
8. King MT, Kenny P, Shiell A et al. Quality of life three months and one year after first treatment for early stage breast cancer: Influence of treatment and patient characteristics. Qual Life Res 2000; 9: 789–800.
9. Ganz PA, Desmond KA, Beth L et al. Quality of life in long-term, disease-free survivors of breast cancer: A follow-up study. J Natl Cancer Inst 2002; 94: 39–49.
10. Ganz PA, Greendale GA, Petersen L et al: Breast cancer in younger women: Reproductive and late health effects of treatment. J Clin Oncol 2003; 21: 4184–93.
11. Hurny C, Bernhard J, Coates AS et al. Impact of adjuvant therapy on quality of life in women with node positive operable breast cancer: International Breast Cancer Study Group. Lancet 1996; 347: 1279–84.
12. Bernhard J, Hurny C, Coates AS et al. Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The IBCSG approach: The International Breast Cancer Study Group. Ann Oncol 1997; 8: 825–35.
13. Bernhard J, Sullivan M, Huerny C et al. Clinical relevance of single item quality of life indicators in cancer clinical trials. Br J Cancer 2001; 84: 1156–65.
14. Hurny C, Bernhard J, Coates A et al. Responsiveness of a single-item indicator versus a multi-item scale: Assessment of emotional well-being in an international adjuvant breast cancer trial. Med Care 1996; 34: 234–48.
15. Hurny C, Bernhard J, Bacchi M et al. The Perceived Adjustment to Chronic Illness Scale (PACIS): A global indicator of coping for operable breast cancer patients in clinical trials: Swiss Group for Clinical Cancer Res (SAKK) and the International Breast Cancer Study Group (IBCSG). Support Care Cancer 1993; 1: 200–8.
16. Hurny C, van Wegberg B, Bacchi M et al. Subjective health estimations (SHE) in patients with advanced breast cancer: An adapted utility concept for clinical trials. Br J Cancer 1998; 77: 985–91.
19. Bonetti M, Gelber RD. A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med 2000; 19: 2595–609.
20. Bonetti M, Gelber RD. Patterns of treatment effects in subsets of patients in clinical trials. Bio-statistics 2004; 5: 465–81.
21. Stearns V, Ullmer L, Lopez JF et al. Hot flushes. Lancet 2002; 360: 1851–61.
22. Avis NE, Assmann SF, Kravitz HM et al. Quality of life in diverse groups of midlife women: Assessing the influence of menopause, health status and psychosocial and demographic factors. Qual Life Res 2004; 13: 933–46.
23. Bernhard J, Zahrieh D, Coates AS et al. Quantifying trade-offs: Quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. Br J Cancer 2004; 91: 1893–901.
24. International Breast Cancer Study Group: Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: Is chemotherapy necessary for premenopausal women with node-positive, endocrine responsive breast cancer? First results of International Breast Cancer Study Group Trial 11–93. Breast 2001; (suppl. 3) 10: 130–8.
25. Berglund G, Nystedt M, Bolund C et al. Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: A prospective randomized study. J Clin Oncol 2001; 19: 2788–96.
26. Fallowfield L, Cella D, Cuzick J et al. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 2004; 22: 4261–71.
27. Hunter MS, Grunfeld EA, Mittal S et al. Menopausal symptoms in women with breast cancer: Prevalence and treatment preferences. Psychooncology 2004; 13: 769–78.

________________________________________________

Jurg Bernhard, David Zahrieh, Monica Castiglione-Gertsch, Christoph Hurny, Richard D. Gelber, John F. Forbes, Elizabeth Murray, John

Collins, Stefan Aebi, Beat Thurlimann, Karen N. Price, Aron Goldhirsch, Alan S. Coates
J Clin Oncol 25: 263–70. © 2007 by American Society of Clinical Oncology